Menu Search
Equities

CellSeed Inc

7776:TYO

CellSeed Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)785.00
  • Today's Change-14.00 / -1.75%
  • Shares traded7.43m
  • 1 Year change+91.46%
  • Beta0.9253
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year CellSeed Inc had net income fall 11.43% from a loss of 759.68m to a larger loss of 846.53m despite a 50.39% increase in revenues from 126.43m to 190.13m.
Gross margin55.38%
Net profit margin-479.79%
Operating margin-476.86%
Return on assets-42.79%
Return on equity-50.38%
Return on investment-46.02%
More ▼

Cash flow in JPYView more

In 2023, CellSeed Inc increased its cash reserves by 101.76%, or 1.09bn. Cash Flow from Financing totalled 1.81bn or 954.17% of revenues. In addition the company used 779.44m for operations while cash from investing totalled 56.32m.
Cash flow per share-30.58
Price/Cash flow per share--
Book value per share63.29
Tangible book value per share63.29
More ▼

Balance sheet in JPYView more

CellSeed Inc appears to have a strong balance sheet and has grown its cash reserves consistently over the last four years to total 2.16bn.
Current ratio16.78
Quick ratio16.42
Total debt/total equity0.0697
Total debt/total capital0.0651
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.